ZURICH (Reuters) – Roche immunotherapy Tecentriq has won European Union approval for treating advanced lung and bladder cancer, the Swiss drugmaker said.
The European Commission approved Tecentriq, also known as atezolizumab, as a monotherapy for locally advanced or metastatic non-small...
https://goo.gl/6sejFG
Sunday, 24 September 2017
Roche cancer immunotherapy Tecentriq wins EU approval
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment